We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,766 hedge funds and large institutions have $62.7B invested in Bristol-Myers Squibb in 2018 Q4 according to their latest regulatory filings, with 208 funds opening new positions, 555 increasing their positions, 748 reducing their positions, and 155 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more first-time investments, than exits

New positions opened: 208 | Existing positions closed: 155

2% more funds holding

Funds holding: 1,7301,766 (+36)

0.61% more ownership

Funds ownership: 73.88%74.49% (+0.61%)

1% less call options, than puts

Call options by funds: $1.13B | Put options by funds: $1.14B

2% less funds holding in top 10

Funds holding in top 10: 4241 (-1)

16% less capital invested

Capital invested by funds: $74.8B → $62.7B (-$12.1B)

26% less repeat investments, than reductions

Existing positions increased: 555 | Existing positions reduced: 748

Holders
1,766
Holders Change
+36
Holders Change %
+2.08%
% of All Funds
39.34%
Holding in Top 10
41
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-2.38%
% of All Funds
0.91%
New
208
Increased
555
Reduced
748
Closed
155
Calls
$1.13B
Puts
$1.14B
Net Calls
-$12.3M
Net Calls Change
-$94.7M
Name Holding Trade Value Shares
Change
Change in
Stake
RI
126
RTW Investments
New York
$49.4M +$205K +3,819 +0.4%
DZ Bank
127
DZ Bank
Germany
$49.3M +$52M +966,906 New
H
128
Hexavest
Quebec, Canada
$47.5M -$47.9M -891,813 -49%
Stifel Financial
129
Stifel Financial
Missouri
$47.3M -$1.79M -33,359 -4%
Skandinaviska Enskilda Banken (SEB)
130
Skandinaviska Enskilda Banken (SEB)
Sweden
$45.7M +$20.5M +382,196 +77%
LCOV
131
London Company of Virginia
Virginia
$45.5M -$2.57M -47,891 -5%
AG
132
Aperio Group
California
$44.6M -$3.78M -70,319 -8%
RG
133
Redmile Group
California
$44.4M +$45.9M +854,700 New
MAMU
134
Marathon Asset Management (UK)
United Kingdom
$44.4M +$8.65M +161,029 +23%
GIA
135
Gateway Investment Advisers
Ohio
$42.9M +$3.06K +57 +0%
RCM
136
RNC Capital Management
California
$42.6M -$2.83M -52,704 -6%
Lazard Asset Management
137
Lazard Asset Management
New York
$42.1M -$6.15M -114,521 -12%
WorldQuant Millennium Advisors
138
WorldQuant Millennium Advisors
New York
$41M +$12M +223,138 +39%
NSLI
139
Nan Shan Life Insurance
Taiwan
$40.9M -$4.69M -87,200 -10%
AA
140
ALPS Advisors
Colorado
$40.7M +$39.1M +728,580 +1,325%
MSV
141
MN Services Vermogensbeheer
Netherlands
$40.6M +$33.9M +630,792 +241%
Marshall Wace
142
Marshall Wace
United Kingdom
$39.9M -$5.36M -99,754 -11%
Aviva
143
Aviva
United Kingdom
$39.1M -$10.2M -190,358 -20%
Federated Hermes
144
Federated Hermes
Pennsylvania
$38.6M +$8.24M +153,414 +26%
KeyBank National Association
145
KeyBank National Association
Ohio
$38.5M -$1.47M -27,404 -4%
HighTower Advisors
146
HighTower Advisors
Illinois
$38.1M -$2.3M -42,746 -6%
GF
147
Gabelli Funds
New York
$37.5M -$161K -3,000 -0.4%
RFC
148
Regions Financial Corp
Alabama
$37.5M -$1.29M -23,933 -3%
SLAM
149
Swiss Life Asset Management
$36.6M -$2.25M -41,855 -6%
VanEck Associates
150
VanEck Associates
New York
$36M +$2.45M +45,599 +7%

BMY Hedge Fund Activity: Q4 2018 in Review

1,766 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2018, worth a combined $62.7B — down 16% from $74.8B a quarter earlier.

Buyers outnumbered sellers: 208 funds opened new BMY positions and 155 closed out — a net gain of 53 holders — while 555 added to existing stakes and 748 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $517M. The largest seller was Jennison Associates, cutting an estimated $558M.

  • 1,766 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2018, up from 1,730 in Q3 2018.
  • Funds reported $62.7B of Bristol-Myers Squibb stock for Q4 2018, down 16% quarter-over-quarter.
  • 208 funds opened new Bristol-Myers Squibb positions in Q4 2018 and 155 closed out, a net change of +53 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2018 was Dodge & Cox, an estimated $517M added.
  • The largest Bristol-Myers Squibb seller in Q4 2018 was Jennison Associates, an estimated $558M sold.

Based on aggregated 13F filings for Q4 2018.